Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability, and immunogenicity of modified-process recombinant hepatitis B vaccine in healthy Norwegian infants
2006-001638-42Phase 3Completed
- Sponsor
- MSD
- Start
- Jul 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of hepatitis b vaccine recombinant in hepatitis B (HBV) (2 arms), sponsored by MSD. Primary endpoints: Seroprotection rate at 1 month after third dose, Geometric mean titer of anti-HBs at 1 month after third dose and 1 more. Started Jul 2006; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on 2006-001638-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001638-42.